Monocyte Subsets in Patients with Chronic Heart Failure Treated with Cardiac Resynchronization Therapy

Figures

• 

  Figure 1. Gating strategy of monocyte analysis with the use of flow cytometry.

• 

  Figure 2. Monocyte subsets in control (Ctrl), patients with heart failure with reduced ejection fraction, who were not qualified for cardiac resynchronization therapy (HFrEF without CRT), and HFrEF patients qualified for cardiac resynchronization therapy (HFrEF with CRT) at baseline. Frequency of (A) classical (CD14++CD16−) (B) intermediate (CD14++16+), and (C) nonclassical (CD14+16++) monocytes. * p < 0.05.

• 

  Figure 3. Monocyte subsets in patients with heart failure with reduced ejection fraction (HFrEF) who qualified for cardiac resynchronization therapy (CRT) at baseline (0) and at 6-month follow-up (6). (A) classical (CD14++CD16−) (B) intermediate (CD14++16+), and (C) nonclassical (CD14+16++) monocytes. Monocyte subsets in 6-month follow-up after CRT device implantation compared to controls (D) classical (CD14++CD16−) (E) intermediate (CD14++16+), and (F) nonclassical (CD14+16++) monocytes.* p < 0.05; ** p < 0.01.